18. Resistant hypertension: The role of personalized therapy in the era of precision medicine
Main Article Content
Abstract
Resistant hypertension is defined as blood pressure that remains above target despite treatment with at least three antihypertensive agents, including a diuretic, at optimal doses. This subset of patients carries a high risk of cardiovascular events and target-organ damage. In the era of precision medicine, personalized therapy-tailoring treatment regimens according to biological, genetic, comorbid, and behavioral characteristics of the patient-has emerged as an essential approach in the management of resistant hypertension. In Vietnam, the implementation of personalized therapy for resistant hypertension still faces considerable challenges related to resources and healthcare infrastructure; however, this strategy aligns with modern medical trends and holds promise for improving treatment outcomes and reducing the disease burden associated with resistant hypertension.
Article Details
Keywords
Resistant hypertension, personalized therapy, precision medicine
References
2. Hội Tăng huyết áp Việt Nam. Đồng thuận quan điểm một số chuyên gia về chiến lược thực hành lâm sàng quản lý tăng huyết áp tại Việt Nam. 2024.
3. Chattranukulchai P, Charnkaew K, Siritantikorn A, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A clinical consensus statement from the Thai Hypertension Society. Hypertens Res. 2024; 47(9): 2447-2455.
4. Jones DW, Ferdinand KC, Taler SJ, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2025.
5. McEvoy JW, McCarthy CP, Bruno RM, et al; ESC Scientific Document Group. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension: Developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by the European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO). Eur Heart J. 2024; 45(38): 3912-4018.
6. Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018; 72(5): e53-e90.
7. Faconti L, Gupta P, Saunders J, et al. Investigation and management of resistant hypertension: British and Irish Hypertension Society position statement. J Hum Hypertens. 2025; 39(1): 1-14.
8. Brant LCC, Nascimento BR, Passaglia LG, et al. The burden of resistant hypertension across the world. Curr Hypertens Rep. 2022; 24(3): 55-66.
9. Yahr J, Brown E, Taler SJ, et al. Resistant hypertension: a stepwise approach. Cleve Clin J Med. 2023; 90(2): 115-125.
10. Chia R, Pandey A, Vongpatanasin W. Resistant hypertension-defining the scope of the problem. Prog Cardiovasc Dis. 2020; 63(1): 46-50.
11. Parodi R, Liu X, Charchar FJ, et al. Resistant hypertension: diagnosis, evaluation, and treatment practical approach. Eur J Intern Med. 2024; 123: 23-28.
12. Nardoianni G, Bruno RM, Ghiadoni L, Taddei S. New drug strategies for treating resistant hypertension-the importance of a mechanistic, personalized approach. High Blood Press Cardiovasc Prev. 2024; 31(2): 99-112.
13. Noubiap JJ, Nansseu JR, Nyaga UF, Sime PS, Francis I, Bigna JJ. Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients. Heart. 2019; 105(2): 98-105.